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Cannabinoid CB1 Receptors Inhibit 
Gut-Brain Satiation Signaling in  
Diet-Induced Obesity
Donovan A. Argueta1, Pedro A. Perez 1, Alexandros Makriyannis 2 and 
Nicholas V. DiPatrizio1*
1Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States, 
2Center for Drug Discovery, Northeastern University, Boston, MA, United States
Gut-brain signaling controls feeding behavior and energy homeostasis; however, the 
underlying molecular mechanisms and impact of diet-induced obesity (DIO) on these 
pathways are poorly defined. We tested the hypothesis that elevated endocannabinoid 
activity at cannabinoid CB1 receptor (CB1Rs) in the gut of mice rendered DIO by chronic 
access to a high fat and sucrose diet for 60 days inhibits nutrient-induced release of 
satiation peptides and promotes overeating. Immunoreactivity for CB1Rs was present in 
enteroendocrine cells in the mouse’s upper small-intestinal epithelium that produce and 
secrete the satiation peptide, cholecystokinin (CCK), and expression of mRNA for CB1Rs 
was greater in these cells when compared to non-CCK producing cells. Oral gavage of 
corn oil increased levels of bioactive CCK (CCK-8) in plasma from mice fed a low fat 
no-sucrose diet. Pretreatment with the cannabinoid receptor agonist, WIN55,212-2, 
blocked this response, which was reversed by co-administration with the peripherally-
restricted CB1R neutral antagonist, AM6545. Furthermore, monoacylglycerol metabolic 
enzyme function was dysregulated in the upper small-intestinal epithelium from DIO mice, 
which was met with increased levels of a variety of monoacylglycerols including the 
endocannabinoid, 2-arachidonoyl-sn-glycerol. Corn oil failed to affect levels of CCK in 
DIO mouse plasma; however, pretreatment with AM6545 restored the ability for corn oil 
to stimulate increases in levels of CCK, which suggests that elevated endocannabinoid 
signaling at small intestinal CB1Rs in DIO mice inhibits nutrient-induced CCK release. 
Moreover, the hypophagic effect of AM6545 in DIO mice was reversed by co-administration 
with the CCKA receptor antagonist, devazepide. Collectively, these results provide evidence 
that hyperphagia associated with DIO is driven by a mechanism that includes CB1R-
mediated inhibition of gut-brain satiation signaling.
Keywords: CB1R, cholecystokinin, enteroendocrine cell, gut-brain, obesity, satiation
INTRODUCTION
Food intake and energy homeostasis are controlled by a dynamic interplay of gut-brain signaling 
pathways that are not well-defined but are thought to become dysregulated in obesity (Steinert 
et al., 2017). Recent studies in humans and rodents suggest a critical role for the endocannabinoid 
(eCB) system in these processes (DiPatrizio and Piomelli, 2012, 2015; DiPatrizio, 2016). 
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The eCB system is located in cells throughout the body and is 
comprised of the eCBs, 2-arachidonoyl-sn-glycerol (2-AG) and 
anandamide (AEA), their biosynthetic and degradative enzymes, 
and the cannabinoid receptor subtypes 1 and 2 [CB1R and CB2R, 
respectively (Piomelli, 2003; Pertwee, 2015)]. CB1Rs in the brain 
control food intake and energy homeostasis (DiPatrizio and 
Piomelli, 2012; Simon and Cota, 2017); however, targeting central 
CB1Rs with antagonists for the treatment of human obesity led 
to psychiatric side-effects that preclude their use as safe and 
effective anti-obesity therapeutics (Christensen et  al., 2007). In 
contrast, CB1Rs antagonists that are restricted to the periphery 
and do not readily cross the blood-brain barrier are associated 
with improvements in a variety of metabolic parameters in 
rodents, and may be  an effective anti-obesity strategy that is 
devoid of psychiatric side-effects inherent to brain-permeable 
drugs (LoVerme et  al., 2009; Randall et  al., 2010; Cluny et  al., 
2011; DiPatrizio et  al., 2011, 2013, 2015; Tam et  al., 2012, 2017; 
Maccarrone et  al., 2015). Nonetheless, peripheral mechanisms 
influence brain function [e.g., signals from the gut microbiome 
(Cani and Knauf, 2016)]; thus, the impact of disrupting 
endocannabinoid signaling at peripheral CB1Rs on these functions 
is largely unknown and warrants future investigation.
Studies from our lab and others suggest key roles for the 
peripheral eCB system in controlling feeding behavior and 
energy homeostasis (DiPatrizio, 2016; Hillard, 2017; Simon and 
Cota, 2017). Indeed, eCB levels are increased in the small 
intestinal epithelium of rodents (1) during a fast (Gomez et al., 
2002; Izzo et  al., 2009; DiPatrizio et  al., 2015; Argueta and 
DiPatrizio, 2017), (2) after oral exposure to dietary fats (DiPatrizio 
et  al., 2011, 2013), and (3) in a mouse model of western 
diet-induced obesity (DIO) (Argueta and DiPatrizio, 2017). 
Pharmacological inhibition of elevated eCB signaling at small-
intestinal CB1Rs with peripherally-restricted CB1R antagonists 
blocks (1) re-feeding after a fast (DiPatrizio et  al., 2015), (2) 
intake of dietary fats based on their orosensory properties 
(DiPatrizio et al., 2011, 2013), and (3) overeating (i.e., increased 
meal size and caloric intake) associated with DIO, (Argueta 
and DiPatrizio, 2017). These studies suggest that the eCB system 
in the small intestinal epithelium plays a key role in feeding 
behavior and energy balance, and becomes dysregulated in DIO.
The mechanism(s) underlying eCB control of gut-brain signaling 
and its dysregulation in DIO is largely unknown. Nonetheless, 
CB1Rs are expressed on the afferent vagus nerve and suggested 
to control feeding behavior and energy balance by directly 
modifying gut-brain vagal signaling important for food intake 
(Burdyga et  al., 2004, 2006). For example, expression of CB1Rs 
in the rat nodose ganglion is upregulated after fasting, and 
refeeding or administration of the gut-derived satiation peptide, 
cholecystokinin (CCK), reversed this effect (Burdyga et al., 2004, 
2010). Moreover, both, fasting-induced increases in CB1R expression 
in the nodose ganglion and the ability for CCK to decrease this 
response were blunted in rats fed a high-fat diet (Cluny et  al., 
2013). Vianna and colleagues, however, reported that select deletion 
of CB1Rs on the afferent and efferent vagus nerve had no effect 
on food intake or body weight in mice fed a standard rodent 
chow or high-fat diet (Vianna et al., 2012). These findings suggest 
that CB1Rs expressed on the vagus nerve may be  dispensable 
for feeding behavior and maintenance of body weight.
Dietary fats and other macronutrients are sensed by 
enteroendocrine cells in the small intestinal epithelium and 
stimulate release of satiation peptides including CCK (McLaughlin 
et  al., 1998, 1999; Raybould et  al., 2006; Steinert et  al., 2017), 
which controls meal size and satiation by activating CCKA receptors 
on the afferent vagus nerve (Smith et  al., 1981, 1985; Schwartz 
and Moran, 1994; Raybould, 2007; Dockray, 2013; Kaelberer 
et al., 2018; Schwartz, 2018) and possibly in the brain (Reidelberger 
et  al., 2004; Ripken et  al., 2015). Furthermore, CCK-containing 
I-cells in the upper small intestinal epithelium of mice express 
genes for CB1Rs (Sykaras et  al., 2012). Thus, CB1Rs in the small 
intestinal epithelium may control feeding behavior by an indirect 
mechanism that includes controlling release of gut-derived satiation 
peptides. We investigated this possibility by testing the hypothesis 
that elevated endocannabinoid activity at CB1Rs in the gut of 
mice rendered DIO by chronic access to a high-fat and sucrose 
diet inhibits nutrient-induced release of satiation peptides, which 
in turn, leads to overeating by delaying satiation.
MATERIALS AND METHODS
Animals
Eight-week old C57BL/6 mice (Taconic, Oxnard, CA, USA) 
were group-housed with ad libitum food and water access and 
maintained on a 12  h dark/light cycle. C57BL/6-Tg 
(Cck-EGFP)2Mirn/J mice with enhanced green fluorescent 
protein on the promoter for cholecystokinin were used for 
immunohistochemistry and fluorescence-activated cell sorting 
(FACS) of small intestinal CCK-containing cells (Jackson 
Laboratories, Bar Harbor, ME, USA). Test diets included Teklad 
2020x soy-purified Standard Rodent Chow (SD; Envigo, 
Huntingdon, UK) or Western-style diet (WD; Research Diets 
D12709B, New Brunswick, NJ, USA; 40% kcal as fat, 43% 
kcal as carbohydrates, mainly sucrose). Body weights were 
recorded every other day at noon. To assess feeding behaviors, 
mice were single-housed in behavior chambers (TSE Systems, 
Chesterfield, MO, USA). All procedures met the U.S. National 
Institute of Health guidelines for care and use of laboratory 
animals and were approved by the Institutional Animal Care 
and Use Committee of the University of California, Riverside.
Feeding Behaviors
Animals were placed into feeding chambers 5 days prior to 
recording for acclimation, and testing began at 60  days after 
being placed on their respective experimental diets. Feeding 
behaviors were assessed starting 1  h prior to dark cycle 
Abbreviations: 2-AG, 2-Arachidonoyl-sn-glycerol; Abhd6, alpha-beta-hydrolyzing 
domain 6; AEA, Anandamide; AM, AM6545; CB1R, Cannabinoid receptor subtype 1; 
CB2R, Cannabinoid receptor subtype 2; CCK, Cholecystokinin; CO, Corn oil; DAG, 
Diacylglycerol; Dev, Devazepide; DGL, Diacylglycerol lipase; DIO, Diet-induced 
obesity; eCB, Endocannabinoid; eGFP, Enhanced green fluorescent protein; FAAH, 
Fatty acid amide hydrolase; FACS, Fluorescence activated cell sorting; FAE, Fatty 
acid ethanolamide; MAG, Monoacylglycerol; MGL, Monoacylglycerol lipase; NAPE-
PLD, N-acyl phosphatidylethanolamine-specific phospholipase D; SD, Standard diet; 
WD, Western diet; WIN, WIN 55,212-2.
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(1,700  h) over a 24  h period for acclimation and for 12  h 
following drug administrations. Behavioral parameters include 
total caloric intake, average meal size, average rate of intake, 
average number of meals, first meal size, average meal duration, 
and average post meal interval. Data were processed using 
TSE Phenomaster software.
Chemicals and Administration Schedule
AM6545, a peripherally-restricted CB1R neutral antagonist, was 
given by IP injection at 10  mg per kg (Northeastern University 
Center for Drug Discovery, Boston, MA, USA). Devazepide 
(Tocris, Bristol, UK), a CCKA receptor antagonist, was given IP 
at 0.3 mg per kg. Both drugs were dissolved in vehicle consisting 
of 7.5% DMSO, 7.5% Tween80, and 85% sterile saline, and 
warmed in a water bath to ensure solubility. All control conditions 
were matched, using vehicle in place of drugs and injections 
occurred 1  h prior to behavior recording (1,600  h). A 72-h 
washout period was allowed between drug treatments. JZL184 
(Tocris, Bristol, UK), a potent inhibitor of monoacylglycerol lipase 
(MGL), was used to prevent monoacylglycerol hydrolysis in the 
diacylglycerol lipase (DGL) assay and to validate our MGL assay 
(described below). Tetrahydrolipstatin (Tocris, Bristol, UK), a 
lipase inhibitor used routinely to study DGL activity (Gregg 
et al., 2012; Jung et al., 2012), was used to validate our DGL assay.
Measurement of Intestinal Lipids
Tissue Harvest and Lipid Extraction
Animals were anesthetized with isoflurane at time of tissue 
harvest (1,500–1,700  h) following ad libitum food and water 
access. Blood was collected by cardiac puncture and deposited 
into vacutainers containing EDTA; plasma was collected as 
supernatant following 10  min centrifugation at 1,500  g (kept 
at 4°C). Jejunum was quickly removed and washed in phosphate-
buffered saline (PBS), opened longitudinally on a stainless steel 
tray on ice, and contents were removed. Jejunum mucosa was 
isolated using glass slides to scrape the epithelial layer and was 
snap-frozen in liquid N2. Samples were stored at −80°C pending 
analysis. Frozen tissues were weighed and then homogenized 
in 1  ml methanol solution containing 500  pmol [2H5]-2-AG 
(Cayman Chemicals, Ann Arbor, MI) as an internal standard. 
Lipids were extracted as previously described (Argueta and 
DiPatrizio, 2017) and resuspended in 0.1 ml methanol:chloroform 
(9:1) and analyzed via ultra-performance liquid chromatography 
tandem mass spectrometry (UPLC-MS/MS).
LCMS Detection of 2-Arachidonoyl-sn-Glycerol 
and Other Monoacylglycerols
Data were acquired using an Acquity I  Class UPLC with direct 
connection to a Xevo TQ-S Micro Mass Spectrometer (Waters 
Corporation, Milford, MA, USA) with electrospray ionization 
(ESI) sample delivery. Lipids were separated using an Acquity 
UPLC BEH C18 column (2.1  mm × 50  mm i.d., 1.7  μm, Waters 
Corporation) and inline Acquity guard column (UPLC BEH 
C18 VanGuard PreColumn; 2.1 mm × 5 mm i.d.; 1.7 μm, Waters 
Corporation), and eluted by a gradient of water and methanol 
(containing 0.25% acetic acid, 5  mM ammonium acetate) 
at a flow rate of 0.4  ml per min and gradient: 80% methanol 
0.5  min, 80 to 100% methanol 0.5–2.5  min, 100% methanol 
2.5–4.5  min, 100 to 80% methanol 4.5–4.6  min, and 80% 
methanol 4.6–5.5  min. The column was maintained at 40°C, 
and samples were kept at 10°C in accompanying sample manager. 
MS/MS detection was in positive ion mode with capillary voltage 
maintained at 1.10 kV, and argon (99.998%) was used as collision 
gas. Cone voltages and collision energies for respective analytes: 
2-AG (20:4) = 30v, 12v; 2-DG (22:6) = 34v, 14v; 2-PG (16:0) = 18v, 
10v; 2-OG (18:1)  =  42v, 10v; 2-LG (18:2)  =  30v, 10v; 
monononadecadienoin (19:2 monoacylglycerol; product of DGL 
assay, see below in “DGL Activity Assay”)  =  18v, 10v; and 
[2H5]-2-AG  =  25v, 44v. Lipids were quantified using a stable 
isotope dilution method detecting H+ or Na+ adducts of the 
molecular ions [M  +  H/Na]+ in multiple reaction monitoring 
(MRM) mode. Acyl migration occurs in monoacylglycerols; thus, 
the sum of 2-AG and 1-AG is presented. Tissue processing and 
LCMS analyses for experiments occurred independently of other 
experiments. Extracted ion chromatograms for MRM transitions 
were used to quantify analytes: 2-AG (m/z  =  379.3  >  287.3), 
2-DG (m/z = 403.3 > 311.1), 2-PG (m/z = 331.3 > 239.3), 2-OG 
(m/z  =  357.4  >  265.2), 2-LG (m/z  =  355.3  >  263.3), 19:2 
monoacylglycerol (m/z  =  386.4  >  277.2), and [2H5]-2-AG 
(m/z  =  384.3  >  93.4), which was used as an internal standard 
for quantitation of monoacylglycerols.
ELISA Analysis of CCK-8 Octapeptide
Mice were fasted for 12 h in order to ensure an empty stomach. 
Mice were pretreated with CB1R ligands, then administered 
corn oil (0.5  ml) by oral gavage 30  min later. Levels of CCK-8 
were assessed in blood plasma 30 min following gavage. Blood 
was placed in BD vacutainer lavender-top EDTA blood collection 
tubes on ice and plasma obtained by centrifugation of tubes 
at 1,500  g for 10  min at 4°C by a sensitive and selective 
CCK-8 ELISA (Cloud Clone Corp; Katy, TX, USA). Mice were 
maintained for 60  days on standard diet (SD) and given IP 
injection of vehicle or the general cannabinoid receptor agonist, 
WIN55,212-2 (3 mg per kg), or WIN 55,212-2  in combination 
with the peripherally-restricted CB1R antagonist, AM6545 (10 mg 
per kg). In addition, mice maintained for 60 days on Western 
diet (WD) were given IP injection of vehicle or AM6545 
(10  mg per kg). ELISA reaction was measured using iMark 
microplate reader (BioRad, Hercules, CA, USA).
Immunohistochemistry
Intact proximal small intestine was removed, and contents were 
flushed with ice-cold 4% paraformaldehyde (PFA)/PBS, then 
fixed in 4% PFA for 4  h at 4°C. Samples were transferred to 
20% sucrose/PBS and incubated for 1 day at 4°C for 
cryopreservation. Cross sections of upper small intestine were 
cut and frozen in OCT (Fisher Healthcare, Chino, CA, USA) 
on dry ice. About 16  μm sections were taken on a cryostat 
(Leica) and mounted onto charged glass slides. Sections were 
permeabilized with 0.5% Tween-20/PBS and then blocked with 
0.1% Tween in casein solution (Thermo Fisher). Primary 
antibodies from rabbit for Cholecystokinin (CCK; ABcam, 
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Cambridge, UK) and Cannabinoid Receptor 1 (Generously 
provided by Dr. Ken Mackie, Indiana University) were diluted 
1:500  in blocking buffer and separately added to slides. Slides 
were washed three times with 0.1% Tween/PBS solution before 
being incubated with AlexaFluor 647 (Donkey anti-rabbit, 
Thermo Fisher). Tissue was washed again and mounted with 
Prolong Gold Antifade reagent with DAPI (Thermo Fisher) 
for nuclear counterstaining. Images were obtained at room 
temperature using an Axio Observer Z1 Inverted Microscope 
(Zeiss, Oberkochen, Germany) at 63× magnification with a 
CSU-X1 Confocal Scanner Unit (Yokogawa, Tokyo, Japan), and 
images were captured using a Prime 95B Scientific CMOS 
Camera (Photometrics, Huntington Beach, CA, USA). Micro-
Manager open source software was used for image capture, 
and final images were optimized using ImageJ 1.51n (NIH, 
Bethesda, MD, USA).
Fluorescence-Activated Cell Sorting
Isolation of Intestinal Epithelial Cells
Approximately, 4  cm of proximal small intestine was inverted 
and mechanically disrupted with frosted glass slides into ice-cold 
buffer containing 5% BSA, 0.6  mM dithiothreitol (DTT) and 
1  mM EDTA in PBS to disrupt mucosal cell layer. Live cells 
were counted following trypan blue staining and 20 × 106 
cells were pelleted at 200  g for 5  min and resuspended in 
1 ml of 3% BSA containing 1 mM EDTA in PBS. Cell suspension 
was filtered through 30-micron mesh and subsequently processed 
by fluorescence-activated cell sorting (FACS).
FACS Sorting of eGFP (+) and eGFP (−) Cells
Isolated cells were sorted and analyzed on a MoFlo Astrios 
(Beckman Coulter, Brea, CA, USA). Debris was detected and 
excluded using forward and side scatter profiles generated with 
a 488 nm laser. eGFP positive (+) cells were detected by fluorescence 
intensity, using excitation and emission spectra of 488 and 513/26, 
respectively. A wild-type mouse from C57Bl/6  J background 
was used to establish autofluorescence, and gating for eGFP was 
used for final sorting (See Figures 1D,E). Samples were sorted 
into fresh resuspension buffer prior to qPCR analysis of gene 
expression. Mice were fasted for 10 h prior to acquisition of cells.
Enzyme Activity Assays
Tissue Preparation
Intestinal epithelium was collected as described above (2.3.1) 
and approximately 100  mg of frozen tissue was homogenized 
in 2  ml of ice-cold 50  mM Tris-HCl, 320  mM sucrose (pH 
7.5) buffer. Homogenates were centrifuged at 800  g for 10  min 
at 4°C and supernatant was collected. Protein supernatants 
were sonicated twice for 10  s and then freeze-thawed in liquid 
nitrogen twice. Samples were spun again, and supernatant 
protein content was quantified using BCA assay and diluted 
to working concentration with Tris-HCl/sucrose buffer.
A
E
I
B
F
J
C
G
K
D
H
L
FIGURE 1 | CB1Rs co-localize with CCK-containing cells in the upper small-intestinal epithelium. Immunohistochemical detection of eGFP [CCK-eGFP  
(B, F, J)] and CB1Rs [CB1R-ab (C, G, K)] reveals co-localization [merge (A, E, I)] in villi of intestinal epithelium. Arrows indicate separate enteroendocrine cells that 
contain immunoreactivity for CB1Rs that co-localize with CCK-eGFP cells. Representative images from three CCK-eGFP mice [DAPI stain (D,H,L)].
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DGL Activity Assay
Small-intestinal epithelial tissue homogenates (25  μg, room 
temperature) were incubated with the MGL inhibitor, JZL184 
(0.3  μM), for 10  min in order to block MGL activity during 
the assay. Homogenates were then incubated in 0.2 ml solution 
of Tris-HCL with 0.2% Triton X-100 (pH 7.0) containing 
20  nmol dinonadecadienoin (19:2 DAG) at 37°C for 30  min. 
Reactions were stopped by adding 1  ml of ice-cold MeOH 
containing 25  pmol [2H5]-2-AG as internal standard. Lipids 
were extracted and the product of the reaction, 
monononadecadienoin (19:2 monoacylglycerol), was analyzed 
via UPLC/MS/MS as described above for 19:2 monoacylglycerol 
(See “LCMS Detection of 2-Arachidonoyl-sn-Glycerol and 
Other Monoacylglycerols”).
MGL Activity Assay
Small-intestinal epithelial tissue (10  μg) was incubated with 
0.4 ml solution of Tris-HCL with 0.1% BSA (pH 8.0) containing 
50  nmol nonadecadienoin (19:2 monoacylglycerol; Nu-Chek 
Prep, Waterville, MN, USA; final volume 0.5 ml per reaction) 
at 37°C for 10  min. Reactions were stopped by adding 1  ml 
of MeOH containing 10  nmol heptadecanoic acid (17:1 FFA; 
Nu-Chek Prep) as internal standard. Lipids were extracted 
and the product of the reaction (19:2 free fatty acid) was 
analyzed via UPLC/MS/MS according to the following protocol. 
Data were acquired using equipment described above (See 
“LCMS Detection of 2-Arachidonoyl-sn-Glycerol and Other 
Monoacylglycerols”) and eluted by a gradient of water and 
methanol (containing 0.25% acetic acid, 5  mM ammonium 
acetate) at a flow rate of 0.4  ml per min and gradient: 90% 
methanol 0.1  min, 90–100% methanol 0.1–2.0  min, 100% 
methanol 2.0–2.1  min, 100 to 90% methanol 2.1–2.2  min, 
and 90% methanol 2.2–2.5  min. Column was maintained at 
40°C and samples were kept at 10°C in sample manager. 
MS detection was in negative ion mode with capillary voltage 
maintained at 3.00  kV. Cone voltages for nonadecadienoic 
acid (19:2 FFA) = 48v and heptadecanoic acid (17:1 FFA) = 64v. 
Lipids were quantified using a stable isotope dilution method 
of proton adducts of the molecular ions [M–H]− in selected 
ion recording (SIR) mode. Tissue processing and LCMS 
analyses for experiments occurred independently of other 
experiments. Extracted ion chromatograms for SIR masses 
were used to quantify analytes: 19:2 FFA (m/z = 293.2) product 
of MGL enzyme assay and 17:1 FFA (m/z  =  267.2) as 
internal standard.
Gastric Emptying
To evaluate drug or endogenous endocannabinoid effects on 
gastric emptying, corn oil was spiked with 1.0  nmol 19:2 
FFA and administered by oral gavage (500 μl), then quantities 
of 19:2 FFA remaining in the stomach were evaluated at 
the time of blood collection 30 min after gavage. The stomach 
was removed and immediately placed into methanol containing 
17:1 FFA as internal standard. Lipids were extracted and 
19:2 FFA was detected and quantified as above (See “MGL 
Activity Assay”).
Gene Expression Analysis
RNA Isolation From Intestinal Epithelium
Total RNA was extracted from intestinal epithelium using 
RNeasy kit (Qiagen, Valencia, CA, USA) method, and first-
strand complementary DNA was generated using M-MLV 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). All 
surfaces for tissue collection and processing were sanitized 
using 70% ethanol and then treated with an RNAse inhibitor 
(RNAse out, G-Biosciences, St. Louis, MO, USA) to maintain 
integrity of isolated RNA. Reverse transcription of total RNA 
(1  μg epithelium) was performed as previously described 
(Argueta and DiPatrizio, 2017).
RNA Isolation From Sorted Cells
Sorted cell suspensions were pelleted at 3,000  g for 10  min 
and resuspended in 0.5  ml of Qiazol (Qiagen, Valencia, CA) 
and subsequently processed using RNeasy kit to isolate total 
RNA. Reverse transcription was performed as described above 
using 50  ng total RNA.
Quantitative Polymerase Chain Reaction Analysis
RT-qPCR was carried out using PrimePCR Sybr Green Assays 
(Biorad, Hercules, CA, USA) with the following primers for 
mouse genes: CB1R (Cnr1), CB2R (Cnr2), cholecystokinin (Cck), 
fatty-acid amide hydrolase (Faah), n-acyl phosphatidyl 
ethanolamine-specific phospholipase D (Napepld), diacylglycerol 
lipase alpha (Dagla) and beta (Daglb), monoacylglycerol lipase 
(Mgll), alpha-beta-hydrolyzing domain 6 (Abhd6) with Hprt 
and Actb as housekeeping genes for epithelium and sorted 
cells, respectively. Values are expressed as relative mRNA 
expression based on widely used methods [i.e., delta-delta cq; 
see (Livak and Schmittgen, 2001)]. Reactions were run in 
triplicate for each animal.
Statistical Analysis
Values are expressed as means ± SEM. Unpaired Student’s two-tailed 
t-test was used to compare data for standard diet- and western 
diet-fed groups. Repeated measures two-way ANOVA was used 
for groups measured over time. Additionally, regular one-way 
and two-way ANOVA were used to determine differences in 
multiple groups with post-hoc Sidak’s multiple comparisons tests 
or Newman-Keul’s, as appropriate. Data were analyzed using 
GraphPad Prism6 software. Significance was determined as p < 0.05. 
Statistical outliers were determined using Grubb’s test in all datasets.
RESULTS
CB1Rs Are Expressed in CCK-Containing 
Cells in the Upper Small-Intestinal 
Epithelium
We reported that eCB levels are increased in the upper small-
intestinal epithelium from mice maintained on a Western Diet 
(WD; high-fat and sucrose diet) for 60  days when compared to 
lean controls maintained on a low-fat and low-sugar diet, and 
inhibiting peripheral CB1Rs blocked overeating associated with 
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consumption of WD (i.e., increased meal size, rate of food intake, 
and total caloric intake) (Argueta and DiPatrizio, 2017). To identify 
the molecular underpinnings of gut-brain eCB signaling important 
for feeding behavior and its dysregulation in DIO, we first evaluated 
whether CB1Rs are expressed in cells that produce and secrete 
the satiation peptide, CCK. CCK controls meal size and induces 
satiation by activating CCKA receptors on the afferent vagus nerve 
(Smith et al., 1981, 1985; Schwartz and Moran, 1994; Reidelberger 
et  al., 2004; Raybould, 2007; Dockray, 2013; Ripken et  al., 2015). 
CB1R immunoreactivity was found in CCK-eGFP-positive cells 
from the upper small intestinal epithelium (Figure 1) in a mouse 
line that expresses eGFP selectively in CCK-expressing cells 
[C57BL/6-Tg(Cck-EGFP)2Mirn/J] (Schmidt et  al., 2014). 
Furthermore, immunoreactivity for CCK was co-localized with 
eGFP in the upper small-intestinal epithelium, which confirms 
expression of CCK in eGFP-containing cells from this mouse 
line (Supplementary Figure S1). We, next isolated eGFP-positive 
and eGFP-negative cells from the upper small intestinal epithelium 
by fluorescence-activated cell sorting (FACS). Messenger RNA 
(mRNA) for CB1Rs (Cnr1) was enriched in CCK-eGFP-positive 
cells when compared to CCK-eGFP-negative cells (Figure 2A; 
eGFP-positive  =  1.00  ±  0.24, eGFP-negative  =  0.04  ±  0.04; 
p  =  0.016; data from three mice). Moreover, mRNA for CCK 
was present in CCK-eGFP-positive cells isolated by FACS but 
was not present in CCK-eGFP-negative cells, which highlights 
the specificity of our FACS gating strategy for isolating CCK-eGFP 
cells and further confirms expression of CCK in these cells 
(Figure 2B). Our gating strategy was optimized for sorting of 
eGFP-positive and eGFP-negative events from cells isolated from 
the upper small-intestinal epithelium of CCK-eGFP mice 
(see Figure 2C). Cells from wild-type mice (see Figure 2D) 
show minimal fluorescence at less than 10% of levels found in 
CCK-eGFP cells: eGFP-positive cells comprise 0.63% of total cells 
analyzed from CCK-eGFP mice, and wild-type show 0.06%, likely 
due to autofluorescence (see Supplementary Figure S2 for detailed 
FACS report). These results suggest that CCK-containing I-cells 
in the mouse upper small-intestinal epithelium are enriched in 
expression of CB1Rs.
Peripheral CB1Rs Control Fat-Induced 
CCK Secretion
The arrival of fat and other macronutrients into the duodenum 
stimulates release of a variety of signaling molecules that 
include CCK, which is produced and secreted by 
enteroendocrine I-cells lining the upper small-intestinal 
epithelium (McLaughlin et al., 1999; Raybould, 1999; Raybould 
et  al., 2006; Cvijanovic et  al., 2017; Steinert et  al., 2017). 
We  next tested the hypothesis that CB1Rs control nutrient-
induced release of CCK from the upper small-intestinal 
epithelium. Oral gavage of corn oil (CO) in lean mice 
maintained on a standard rodent diet (SD; low-fat no-sucrose 
chow) increased plasma levels of bioactive CCK, CCK-8 
(octapeptide), when compared to control mice that received 
oral gavage of saline [Figure 3A; CO  =  0.69  ±  0.11  ng per 
ml, saline control  =  0.28  ±  0.02  ng per ml; p  <  0.05 CO 
versus saline control, n  =  3–5). Peripheral administration of 
the general cannabinoid receptor agonist, WIN55,212-2 (WIN, 
3  mg per kg), blocked CO-induced secretion of CCK-8 
(Figure 3A; CO  +  WIN  =  0.36  ±  0.04  ng per ml; p  <  0.05 
CO  +  WIN versus CO alone, n  =  5). Furthermore, the effect 
of WIN administration on CO-induced secretion of CCK-8 
was reversed by co-treatment with the peripherally-restricted 
neutral CB1R-selective antagonist, AM6545 (Figure 3A; 
CO  +  WIN+AM6545  =  0.75  ±  0.14  ng per ml; p  <  0.05 
CO  +  WIN versus CO  +  WIN+AM, n  =  5; AM6545 10  mg 
per kg). These results suggest that exogenous activation of 
CB1Rs inhibits nutrient-induced CCK release from the 
upper gut.
We next tested the hypothesis that elevated endogenous 
activity (e.g., increased 2-AG levels) at upper small-intestinal 
CB1Rs in mice maintained on Western Diet (WD; high-fat 
and sucrose diet) for 60  days inhibits CO-induced increases 
in circulating levels of CCK-8. We  first confirmed that levels 
of 2-AG—among other monoacylglycerols—were increased in 
the upper small intestinal epithelium of WD mice, when 
compared to lean mice fed SD for 60  days (see Table 1). 
Next, we  tested the ability for oral gavage of CO to increase 
A C D
B
FIGURE 2 | CB1R mRNA expression is enriched in CCK-containing cells in the upper small-intestinal epithelium. Fluorescence-activated cell sorting (FACS) of 
eGFP-CCK-positive (+) and eGFP-CCK-negative (−) cells from the upper small-intestinal epithelium reveals enhanced Cnr1 expression in eGFP-CCK-positive cells 
(A). Expression of mRNA for CCK is found in eGFP-CCK-positive cells but not in eGFP-CCK-negative cells (B). Gating strategy shown for sorting of eGFP-positive 
and eGFP-negative events, with eGFP-positive cells highlighted in green and demarked by thin line (C) and compared to upper small-intestinal epithelial cells from a 
wild-type (WT) mouse (D). Data expressed as mean ± S.E.M. Analyzed using Student’s t-test, two-tailed (C); n = 3 per group; *p < 0.05.
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CCK-8 levels in plasma of WD mice. CO failed to affect 
levels of CCK-8  in WD mice when compared to mice fed 
a standard diet (SD) that is low in fat and absent of 
sucrose (Figure 3B; CO  +  WD  =  0.33  ±  0.04  ng per ml, 
CO + SD = 0.8 ± 0.03 ng per ml; p < 0.01, n = 5). Furthermore, 
AM6545 treatment in WD mice that received oral 
gavage of CO increased levels of CCK-8 to those comparable 
to SD mice under the same conditions (Figure 3B; 
CO  +  WD  +  AM  =  0.7  ±  0.1  ng per ml; p  <  0.01 CO  +  WD 
versus CO  +  WD  +  AM, n  =  6). Collectively, these results 
suggest that exogenous or endogenous activation of CB1Rs 
in the upper small intestinal epithelium inhibits nutrient-
induced CCK secretion.
All levels of CCK-8  in these experiments fell within the 
range of the standard curve for CCK-8 quantitation by a 
sensitive and selective CCK-8 ELISA, which shows no cross-
reactivity for gastrin (see Supplementary Figure S3), another 
gut-derived peptide that shares some common molecular 
features with CCK-8 (Walsh et al., 1982; Eysselein et al., 1984; 
Wolfe et  al., 1985; Shulkes and Baldwin, 1997). Furthermore, 
the range of CCK-8 levels in our studies (from 0.27  ±  0.02 
to 0.8  ±  0.03  ng per ml or 0.23  ±  0.02 to 0.7  ±  0.03  nM) 
aligns with reported Ki and EC50 values of sulfated CCK-8  in 
several binding and in vitro bioassays (e.g., amylase release 
from pancreatic acini and ileum contractions in guinea pig) 
(Charpentier et  al., 1988).
CB1R activation is reported to decrease gastric emptying, 
an effect also found in mice fed a high-fat diet for 14  weeks 
(Pertwee, 2001; Di Marzo et  al., 2008). To identify if altered 
gastric emptying occurs under our conditions and may 
contribute in part to inhibited corn oil-induced CCK release, 
we developed a novel UPLC/MS/MS-based method to evaluate 
if CB1R activation with WIN 55,212-2 or exposure to WD 
for 60  days impacts gastric emptying following oral gavage 
of corn oil in SD and WD mice, respectively. Thirty minutes 
after administration of drugs, we administered by oral gavage 
corn oil (500  μl) that contained 19:2 free-fatty acid (1  nmol) 
as a tracer and measured by UPLC/MS/MS the remaining 
quantities of 19:2 free-fatty acid in the stomach 30  min 
after gavage. WIN 55,212-2 (3  mg per kg) alone or in 
combination with AM6545 (10  mg per kg) had no effect 
on gastric emptying of corn oil in SD mice (see Supplementary 
Figure S4A). Similarly, WD mice displayed no changes in 
gastric emptying of corn oil when compared to SD mice 
(see Supplementary Figure S4B). These data suggest that 
exogenous activation (WIN in SD mice) or endogenous 
activation (elevated small intestinal epithelial eCB levels in 
WD mice) of CB1Rs does not affect gastric emptying of 
corn oil under our conditions, and does not likely impact 
CCK release by a mechanism that includes alterations in 
gastric emptying in mice.
CB1Rs in pancreatic beta cells control insulin release and 
glucose homeostasis (Juan-Pico et al., 2006; De Petrocellis et al., 
2007; Bermudez-Silva et  al., 2008; Nakata and Yada, 2008; Li 
et  al., 2010; Gonzalez-Mariscal et  al., 2018). Thus, we  tested if 
drug treatment impacted glucose levels in response to corn oil 
gavage in SD mice, which in turn, could affect gastric emptying, 
motility, or enteroendocrine hormones from small intestinal 
enteroendocrine cells. Glucose levels in blood were collected 
from tail vein and monitored via hand-held glucose monitor 
at (1) time of drug administration, (2) 30  min later just prior 
to corn oil gavage, and (3) 30  min later at time of kill (See 
Supplementary Figure S5). Drug treatment had no significant 
impact on blood glucose levels at any time point prior to or 
after gavage of corn oil (See Supplementary Figure S5). 
A B
FIGURE 3 | Exogenous or endogenous activation of peripheral CB1Rs 
inhibits fat-induced CCK release. Compared to control [0.5 ml saline (Sal) by 
oral gavage and vehicle (Veh) by IP injection], corn oil (CO; 0.5 ml by oral 
gavage) increased levels of CCK-8 in plasma of lean mice fed a low-fat no-
sugar standard diet (SD), an effect blocked by the CB1R agonist, WIN 
55,212-2 (WIN, IP 3 mg per kg 30 min before CO) (A). The effects of WIN 
were inhibited by co-administration with the peripherally-restricted CB1R 
antagonist, AM6545 (AM; 10 mg per kg 30 min before CO). When compared 
to control SD mice (CO + SD), CO failed to elicit changes in levels of CCK-8 in 
plasma in mice fed western diet (WD) for 60 days, and inhibition of peripheral 
CB1Rs with AM6545 normalized levels of CCK-8 to those found in SD CO 
controls (B). Data expressed as means ± S.E.M. Analyzed by one-way 
ANOVA with post hoc Newman-Keuls multiple comparison test. n = 3–5 per 
condition, * p < 0.05, ** p < 0.01.
TABLE 1 | Impact of diet on monoacylglycerols in mouse small-intestinal epithelium.
MAG 20:4 (2-AG)
(nmol g−1)
18:1
(nmol g−1)
18:2
(nmol g−1)
16:0
(nmol g−1)
22:6
(nmol g−1)
Total
(nmol g−1)
SD 80.23 ± 8.542 49.57 ± 9.804 217.7 ± 52.09 33.99 ± 4.125 9.413 ± 1.996 390.9 ± 72.24
WD 132.5 ± 22.20 109.0 ± 22.03 415.3 ± 83.26 150.1 ± 21.53 22.63 ± 3.703 829.4 ± 144.2
p 0.0353 0.0206 0.0554 <0.0001 0.0049 0.0122
MAG, Monoacylglycerol represented as fatty acid chain; SD, Standard diet n = 10; WD, Western diet n = 9. Mean values are shown as ± S.E.M. Bold values are significantly different 
determined by two-tailed unpaired t-test.
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These data suggest that, under our conditions, activating CB1Rs 
does not impact blood glucose levels following oral gavage of 
corn oil in mice.
Activity of Enzymes Responsible for 
Metabolism of 2-AG and Other 
Monoacylglycerols Is Dysregulated in the 
Upper Small-Intestinal Epithelium in Mice 
Chronically Fed WD
We next aimed to identify the mechanism(s) of increased 
2-AG and related monoacylglycerol levels (see Table 1) in 
WD mice by analyzing activity of their biosynthetic 
[diacylglycerol lipase (DGL)] and degradative enzymes 
[monoacylglycerol lipase (MGL)] using our lab’s UPLC/MS/
MS-based functional enzyme assay methods (see Supplementary 
Figure S6 for validation of enzyme assays). When compared 
to SD mice, WD mice displayed an increase in activity of 
DGL (Figure 4A; SD  =  0.12  ±  0.02, WD  =  0.22  ±  0.03  nmol 
per mg protein per min; p  =  0.016, reactions from six mice 
per diet group), and MGL (Figure 4B; SD  =  36.32  ±  3.82, 
WD  =  51.60  ±  4.95  nmol per mg protein per min; p  =  0.035, 
reactions from six mice per diet group) in isolated tissue 
from the upper small intestinal epithelium. Congruent with 
data in Table 1 and (Argueta and DiPatrizio, 2017), these 
effects were met with increased levels of 2-AG in upper small 
intestinal epithelium of separate mice (Figure 4C; 
SD = 45.71 ± 6.93, WD = 92.57 ± 16.41 nmol per g; p = 0.014, 
n  =  9–10 per diet group). See Figure 4D for diagram of the 
2-AG metabolic pathways. Together, these results suggest that 
monoacylglycerol metabolic pathways are dysregulated after 
chronic exposure to WD, which leads to a net increase in 
monoacylglycerols, including 2-AG, in the upper small-
intestinal epithelium.
Expression of Select eCB System 
Components in the Upper Small-Intestinal 
Epithelium Is Dysregulated in Mice 
Chronically Fed WD and Partially 
Conserved in CCK-Positive Cells
Relative expression of mRNA for intestinal CCK, CB1Rs, and 
CB2Rs (Cnr2) was unchanged in whole upper small intestinal 
epithelial scrapings from mice fed WD versus SD mice 
(Figure 5A; CCK, SD  =  1.00  ±  0.76, WD  =  0.56  ±  0.45, 
p = 0.64; Cnr1, SD = 1.00 ± 0.36, WD = 0.79 ± 0.31, p = 0.67; 
Cnr2, SD  =  1.00  ±  0.31, WD  =  0.83  ±  0.19, p  =  0.65; data 
from four mice per diet group). Expression of mRNA for the 
alpha isoform of DGL (Dagla) was also unaffected by diet 
(Figure 5A; SD  =  1.00  ±  0.25, WD  =  0.90  ±  0.29, p  =  0.80); 
however, expression of mRNA for the beta isoform of DGL 
(Daglb) was reduced in WD versus SD mice (Figure 5A; 
SD  =  1.00  ±  0.15, WD  =  0.35  ±  0.03, p  =  0.005), while 
mRNA for MGL (Mgll) and the serine hydrolase alpha/beta 
hydrolase domain 6 (Abhd6) were increased in small intestinal 
epithelium under the same conditions (Figure 5A; Mgll, 
SD  =  1.00  ±  0.17, WD  =  2.71  ±  0.46, p  =  0.013; Abhd6, 
SD  =  1.00  ±  0.16, WD  =  1.54  ±  0.05, p  =  0.02). No changes 
were found for the fatty acid ethanolamide biosynthetic enzyme, 
NAPE-PLD, or the fatty acid ethanolamide degradative enzyme, 
FAAH (Figure 5A; NAPE-PLD, SD  =  1.00  ±  0.18, 
WD  =  0.89  ±  0.08, p  =  0.6; FAAH, SD  =  1.00  ±  0.17, 
WD  =  1.00  ±  0.07, p  =  0.99). Furthermore, the upper small-
intestinal epithelium is enriched in expression of mRNA for 
Daglb when compared to Dagla (Figure 5A inset; 
Dagla  =  1.00  ±  0.19, Daglb  =  29.73  ±  4.3; p  =  0.001; data 
from four mice fed SD).
It is important to note, in contrast to our previous report 
that included analysis of eCB system expression in the upper 
A
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FIGURE 4 | 2-AG biosynthesis and degradation are upregulated in small intestine during obesity. Hydrolytic activity of DGL (A) and MGL (B) are increased in mice 
maintained on western diet (WD) when compared to controls fed a standard diet (SD). Levels of the endocannabinoid, 2-AG, are increased in jejunum mucosa of 
WD mice, when compared to SD mice (C). 2-AG is formed by the hydrolysis of its 1,stearoyl,2-arachidonoyl-sn-glycerol precursor by DGL and is subsequently 
degraded by MGL into arachidonic acid and glycerol (D). Data expressed as mean ± S.E.M. Analyzed using Student’s two-tailed t-test. n = 6 per condition, 
*p < 0.05.
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small intestinal epithelium of mice maintained on WD and 
SD [Lab Diet 5001 used in (Argueta and DiPatrizio, 2017)], 
in this study we  used a soy protein-free Teklad 2020x as a 
control SD in order to eliminate any potential effects of 
phytoestrogen-containing soy protein on eCB metabolism or 
behavior [see (McFarland et  al., 2004; Thors et  al., 2007, 2008; 
Peroni et  al., 2012)]. We  found two differences in results when 
comparing use of the two control diets versus WD. We reported 
no changes in expression of mRNA for the beta isoform of 
DGL and increases in expression of mRNA for FAAH in WD 
mice when compared to control SD mice (Argueta and DiPatrizio, 
2017); however, in this study, we  found decreased expression 
of mRNA for the beta isoform of DGL and no changes in 
expression of mRNA for FAAH in WD mice when compared 
to SD mice. These differences highlight possible effects of diets 
that utilize soy protein on expression of eCB metabolic enzymes 
and eCB metabolic function. A direct comparison of the impact 
of specific control diets on expression of eCB system components, 
however, remains to be  evaluated.
CCK-eGFP-positive cells isolated from mice fed SD or WD 
mice displayed no differences between diet condition in 
expression of mRNA for CCK and components of the eCB 
system that include Cnr1, Cnr2, Daglb, Abhd6, and FAAH 
(Figure 5B; p  >  0.05 not significant, data from three mice 
per diet group). Dagla, Mgll, and Napepld mRNA were below 
detectable levels, which suggest a lack of expression of these 
eCB system components in CCK-containing cells.
Collectively, these results identify select eCB system gene 
transcripts in CCK-containing cells, and changes in expression 
of biosynthetic and degradative enzyme gene transcripts in whole 
epithelium of WD mice that do not fully correspond to changes 
in activity of their proteins, including DGL and MGL (see 
Figure 4). The latter suggests possible post-transcriptional and/
or post-translational changes in expression of these enzymes in 
the upper small-intestinal epithelium in WD mice when compared 
to lean SD mice, although this hypothesis remains to be directly 
tested. Furthermore, a lack of expression of the fatty acid 
ethanolamide (FAE) biosynthetic enzyme, NAPE-PLD, in 
CCK-containing cells suggests that FAEs including anandamide—
which is also found in small intestinal epithelium of rodents 
(Izzo et  al., 2009; DiPatrizio et  al., 2011, 2013, 2015; Argueta 
and DiPatrizio, 2017; Perez and DiPatrizio, 2018)—is generated 
in neighboring cells and therefore may act in a paracrine manner 
with I-cells that contain CB1Rs. In contrast, expression of mRNA 
for the beta isoform of the monoacylglycerol biosynthetic enzyme, 
DGL, is abundantly expressed in CCK-containing cells, which 
suggests that 2-AG may signal at CB1Rs in an autocrine manner 
at these cells. Expression of the primary 2-AG degradative 
enzyme, MGL, is absent in CCK-containing I-cells, which suggests 
that 2-AG is degraded at adjacent cells and therefore may 
additionally signal CB1Rs on adjacent cells in a paracrine manner. 
A comprehensive analysis of eCB system architecture and its 
cell-specific expression in the upper small-intestinal epithelium 
of mice remains for future studies.
Western Diet Exposure for 60 Days Is 
Associated With Obesity and Hyperphagia 
in Male Mice
Consistent with our previous studies (Argueta and DiPatrizio, 
2017), exposure to WD for 60  days, when compared to lean 
mice fed SD for 60  days, was associated with (1) a rapid and 
sustained increase in body mass when compared to control 
mice fed SD for 60  days, (2) increased 24  h meal size, (3) rate 
of food intake, and (4) total 24  h caloric intake (see 
Supplementary Figure S7 and Table 2 for details and data). No 
significant changes were found for other feeding behaviors including 
(1) first meal size, (2) meal frequency, (3) meal duration, and 
(4) post-meal interval. As discussed above in “Expression of Select 
eCB System Components in the Upper Small Intestinal Epithelium 
is Dysregulated in Mice Chronically Fed WD and Partially 
Conserved in CCK-Positive Cells,” in contrast to our previous 
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FIGURE 5 | Expression of select components of the eCB system is dysregulated in the upper small intestine of DIO mice and partially conserved in CCK-eGFP+ cells. 
Expression of mRNA for cholecystokinin (Cck), cannabinoid receptor subtype 1 (Cnr1) and 2 (Cnr2), and other components of the eCB system in upper small-intestinal 
mucosal scrapings are not impacted by western diet (WD) exposure when compared to controls fed a standard diet (SD) (A). Expression of diacylglycerol lipase beta 
(Daglb) is decreased, and expression of the degradative enzymes monoacylglycerol lipase (Mgll) and alpha-beta hydrolyzing domain 6 (Abhd6) are increased in WD mice. 
Expression of mRNA for CCK or components of the eCB system were not significantly affected by diet in eGFP (+) sorted cells (B). Expression of mRNA for diacylglycerol 
lipase alpha (Dagla), Mgll, and N-acyl phosphatidylethanolamine specific phospholipase D (Napepld) was not detected (ND) (B). Data expressed as mean ± S.E.M. 
Analyzed using Student’s two-tailed t-test. n = 3 per group in triplicate and *p < 0.05, **p < 0.01, ***p < 0.001 (A); n = 3 per group in triplicate, p > 0.05 (B).
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study (Argueta and DiPatrizio, 2017), in this study we  used a 
soy-protein-free lab chow. Irrespective of control diet, however, 
WD intake was consistently associated with increased 2-AG levels 
(Table 1) and hyperphagia across relevant parameters in both 
studies (Table 2, Figure 6; Argueta and DiPatrizio, 2017). Together, 
these data suggest that exposure to a WD rapidly induces body 
weight gain that is met with increased meal size, rate of intake, 
and daily caloric intake, when compared to lean controls.
Pharmacological Inhibition of CCKA 
Receptors Blocks the Anorexic Effect of 
AM6545 in Mice Chronically Fed a WD
We next tested the hypothesis that peripheral CB1Rs control 
feeding behavior by a mechanism that includes control of 
CCK-mediated satiation signaling. When compared to vehicle 
treatment in mice fed WD for 60  days, AM6545 treatment 
(10  mg per kg) in WD mice reduced meal size (Figure 6A; 
vehicle = 1.47 ± 0.15 kcal, AM6545 = 1.13 ± 0.67 kcal; p < 0.05, 
n  =  12), rate of intake (Figure 6B; vehicle  =  0.76  ±  0.12  kcal 
per min, AM6545  =  0.46  ±  0.05  kcal per min; p  <  0.01), and 
total caloric intake (Figure 6C; vehicle  =  9.11  ±  0.67  kcal per 
min, AM6545  =  6.62  ±  0.69  kcal per min; p  <  0.01) during 
a 12  h test, which is consistent with our previous findings 
(Argueta and DiPatrizio, 2017). Furthermore, AM6545 treatment 
in mice fed SD for 60  days did not affect meal size 
(Figure 6A; vehicle  =  0.74  ±  0.05  kcal, 
AM6545  =  0.71  ±  0.04  kcal; p  >  0.05, n  =  12), rate of intake 
(Figure 6B; vehicle  =  0.30  ±  0.03  kcal per min, 
AM6545  =  0.32  ±  0.03  kcal per min; p  >  0.05), and total 
caloric intake (Figure 6C; vehicle  =  5.51  ±  0.42  kcal per min, 
AM6545  =  5.45  ±  0.28  kcal per min; p  >  0.05) during a 12  h 
test. Importantly, co-administration of a low dose of the 
CCKA receptor antagonist, devazepide (Dev; 0.1  mg per kg), 
in WD mice blocked the effects of AM6545 on reducing 
meal size (Figure 6A; vehicle  =  1.47  ±  0.15  kcal, 
AM6545  +  devazepide  =  1.49  ±  0.16  kcal; p  >  0.05), rate of 
intake (Figure 6B; vehicle  =  0.76  ±  0.12  kcal per min, 
AM6545  +  devazepide  =  0.62  ±  0.06  kcal per min; p  >  0.05), 
and total caloric intake (Figure 6C; vehicle  =  9.11  ±  0.67  kcal 
per min, AM6545  +  devazepide  =  8.98  ±  0.67  kcal per min; 
p  >  0.05). Administration of devazepide alone affected only 
total 12-h caloric intake in SD mice (Figure 6C; 
vehicle = 5.51 ± 0.42 kcal per min, devazepide = 7.61 ± 0.33 kcal 
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FIGURE 6 | Peripheral eCB signaling drives hyperphagia in mice maintained on a WD via a CCK-dependent mechanism. Caloric intake (A), meal size (B), and rate 
of intake (C) of a western diet (closed bars) are significantly reduced during a 12 h test following inhibition of peripheral CB1Rs with AM6545 (AM, 10 mg per kg), an 
effect absent in low-fat chow fed mice (open bars) and that is blocked by co-administration with the CCKA receptor antagonist, devazepide (Dev; 0.1 mg per kg). 
Diet and drug had no effect on meal frequency (D), meal duration (E), post meal interval (F), or first meal size (G). All data represented as means ± SEM. Analyzed 
using regular 2-Way ANOVA with post hoc Newman-Keuls multiple comparison’s test. n = 11–12 per condition, *p < 0.05, **p < 0.01.
TABLE 2 | Consumption of WD is associated with hyperphagia.
Δ Body mass  
(g)
Meal size  
(kcal)
Intake rate 
(kcal min−1)
24 h Intake 
(kcal)
First meal 
(kcal)
Frequency 
(meals day−1)
Duration  
(Min)
PMI  
(Min)
SD 8.90 ± 0.31 0.69 ± 0.04 0.33 ± 0.02 8.10 ± 0.61 0.72 ± 0.11 11.67 ± 0.45 8.61 ± 1.16 114.7 ± 8.4
WD 18.14 ± 0.46 1.29 ± 0.10 0.71 ± 0.08 13.28 ± 0.81 1.99 ± 0.66 9.83 ± 1.42 6.85 ± 0.98 129.3 ± 14.3
p <0.0001 <0.0001 <0.0001 <0.0001 0.07 0.23 0.26 0.31
PMI, Post meal interval. Mean values are shown as ± S.E.M. n = 10. Bold values are significantly different determined by two-tailed unpaired t-test.
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per min; p  <  0.05). Neither AM6545 nor devazepide affected 
other meal parameters including meal frequency (Figure 6D), 
meal duration, (Figure 6E), post-meal interval (Figure 6F), or 
first-meal size (Figure 6G) in SD or WD mice. These data 
suggest that the acute anorexic effects of AM6545  in WD mice 
are dependent on a mechanism that includes activation of CCKA 
receptors and inhibition of gut-brain satiation signaling.
DISCUSSION
The molecular underpinnings of gut-brain signaling and their 
dysregulation in DIO are poorly defined. Our studies suggest 
that eCB activity at CB1Rs in the upper small intestinal epithelium 
is upregulated in mice chronically fed a WD, which in turn, 
promotes overeating by a mechanism that includes inhibiting 
nutrient-induced gut-brain satiation signaling (see Figure 7 for 
model). Six primary findings support this conclusion: (1) CB1Rs 
are enriched in CCK-containing cells in the mouse upper small 
intestinal epithelium; (2) oral gavage of corn oil increased 
circulating levels of CCK-8  in lean mice, and pharmacological 
activation of CB1Rs blocked this effect, which was reversed by 
inhibition of peripheral CB1Rs with a peripherally-restricted 
CB1R neutral antagonist; (3) levels of 2-AG and other 
monoacylglycerols were increased in the upper-small intestinal 
epithelium of WD mice when compared to lean mice, and this 
effect was associated with dysregulated monoacylglycerol 
metabolism; (4) oral gavage of corn oil failed to affect circulating 
levels of CCK-8 in WD mice, and inhibition of peripheral CB1Rs 
in WD mice restored the ability for corn oil to increase CCK 
levels; (5) pharmacological inhibition of peripheral CB1Rs in 
WD mice blocked overeating associated with increased meal 
size, rate of feeding, and total caloric intake; and (6) the 
hypophagic effects of peripheral CB1R antagonism in WD mice 
were reversed by pretreatment with a low-dose CCKA receptor 
antagonist. Collectively, our studies identify a previously unknown 
role for the eCB system at the interface of nutrient-sensing and 
gut-brain satiation signaling that becomes dysregulated in DIO 
and promotes overeating by delaying satiation.
Our studies suggest that the eCB system in the small 
intestinal epithelium controls feeding behavior by a mechanism 
that includes inhibiting nutrient-induced release of the 
gut-derived satiation peptide, CCK, which in turn increases 
meal size and caloric intake. CCK is secreted from 
enteroendocrine I-cells in the upper small intestinal epithelium 
after nutrients arrive in the lumen (McLaughlin et  al., 1999; 
Raybould et  al., 2006; Steinert et  al., 2017; Kaelberer et  al., 
2018) and controls meal size and induces satiation by activating 
CCKA receptors on afferent vagal fibers (Smith et  al., 1981, 
1985; Schwartz and Moran, 1994; Raybould, 2007; Kaelberer 
et al., 2018; Schwartz, 2018) and possibly the brain (Reidelberger 
et  al., 2004; Ripken et  al., 2015). Indeed, polymorphisms in 
FIGURE 7 | Model of CB1R control of nutrient-induced CCK release. Our studies suggest that cannabinoid CB1Rs in the upper small-intestinal epithelium control 
nutrient-induced satiation signaling, and their signaling is increased in diet-induced obesity, which drives overeating by delaying satiation. The upper small-intestinal 
epithelium contains enteroendocrine I-cells, which are a subpopulation of enterocytes that secrete cholecystokinin (CCK) when nutrients – including dietary fats – 
enter the lumen (Rehfeld, 1998; Tanaka et al., 2008; Wang et al., 2011; Liou et al., 2011a; Brennan et al., 2012). Dietary fats (e.g., corn oil), in the form of 
triacylglycerols, are hydrolyzed in the lumen into mostly monoacylglycerols and free-fatty acids (FFAs) that are sensed by free-fatty acid receptors (FFARs) located on 
enteroendocrine cells in the small-intestinal epithelium. Activation of FFARs stimulates secretion of CCK by a mechanism that requires calcium (Ca2+) influx and/or 
intracellular (i.e., endoplasmic reticulum, ER) mobilization (McLaughlin et al., 1998; Hira et al., 2004; Tanaka et al., 2008). CCK activates CCKA receptors located on 
adjacent afferent sensory vagal fibers, which in turn, communicate with the brain and control meal size and satiation (Smith et al., 1981, 1985; Schwartz and Moran, 
1994; Kaelberer et al., 2018). Consumption of a Western diet (WD) is associated with increased levels of the endocannabinoids (eCBs) and their activity at CB1Rs in 
the upper small-intestinal epithelium, which we propose inhibits CCK release and satiation signaling. The molecular mechanism(s) mediating CB1R control of CCK 
release is unknown, but may include inhibition of Ca2+-mediated CCK release. A future test of this hypothesis is warranted.
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CCKA receptor genes in humans are associated with increased 
meal size and food intake, and obesity (Miller et  al., 1995; 
Marchal-Victorion et  al., 2002; de Krom et  al., 2007). 
Furthermore, CCK in a stabilized form resistant to degradation 
in the GI tract is effective at reducing food intake and body 
weight in DIO rodents (Pierson et  al., 1997; Irwin et  al., 
2012, 2013b), and activating CCKA receptors enhances the 
anti-obesity properties of GLP-1 agonists, amylin, and leptin 
(Trevaskis et  al., 2010, 2015; Irwin et  al., 2013a, 2015).
Gene transcripts and immunoreactivity for CB1Rs were found 
in CCK-containing I-cells in the upper small-intestinal epithelium 
of mice (see Figures 1, 2; Sykaras et  al., 2012). Furthermore, 
the hypophagic effects of AM6545 were blocked by 
co-administration of the CCKA receptor antagonist, devazepide. 
These results suggest that when eCB activity is elevated at local 
CB1Rs in the upper small-intestinal epithelium in DIO, increased 
CB1R activation may inhibit nutrient-induced release of satiation 
peptides from small-intestinal enteroendocrine cells and lead 
to increased meal size and caloric intake. In support of this 
hypothesis, oral gavage of corn oil—which potently increases 
circulating levels of bioactive CCK-8  in lean mice that have 
low levels of small-intestinal eCB levels—failed to affect circulating 
levels of CCK-8  in mice chronically fed WD that have elevated 
eCB levels in the small-intestinal epithelium. Moreover, inhibiting 
elevated eCB signaling at peripheral CB1Rs with AM6545  in 
WD mice—at a dose that blocked overeating—restored the ability 
for corn oil to increase circulating levels of CCK-8.
The mechanisms of CB1R control of nutrient-induced release 
of CCK from enteroendocrine I-cells in the upper small-intestinal 
epithelium are unknown. Nonetheless, a primary mechanism 
by which CB1Rs block neurotransmitter release is by inhibiting 
calcium influx or mobilization (Howlett et  al., 2010; Pertwee, 
2015), and nutrient-induced CCK release is calcium-dependent 
(McLaughlin et  al., 1998; Gevrey et  al., 2002; Hira et  al., 2004; 
Liou et  al., 2011b; Nakajima et  al., 2012). Thus, CB1R activity 
may inhibit release of gut peptides by a mechanism that includes 
inhibiting calcium influx or mobilization; however, a direct 
test of this hypothesis remains to be  performed (see Figure 7 
for proposed mechanism).
It is controversial if obesity impacts CCK secretion [see for 
review, (Steinert et  al., 2017)]. In line with our present findings 
in mice, several studies suggest that CCK secretion is reduced 
in obese humans: fasting CCK levels were lower than non-obese 
(Baranowska et al., 2000) and a trend toward lower CCK release 
after intra-duodenal infusions of oleic acid in overweight or 
obese subjects (Stewart et  al., 2011). Fat-induced CCK secretion 
and satiation induced by CCK administration were also reduced 
in rats fed a high-fat diet (Duca et  al., 2013). Other studies, 
however, reported no differences in CCK levels between obese 
or lean humans following a meal (Brennan et  al., 2012), and 
increases in CCK after a high-fat meal (French et  al., 1993). 
Furthermore, several preclinical studies in rodents suggest that 
sensitivity of vagal afferent neurons to the satiating effects of 
CCK may be  decreased in DIO (Covasa et  al., 2000; Daly et  al., 
2011; Duca et  al., 2013; de Lartigue, 2016). This phenomenon 
may be  due, in part, to changes in membrane properties of 
neurons in the nodose ganglion. The satiating actions of a 
physiological dose of CCK, however, were equally effective in 
suppressing food intake in obese and lean human subjects 
(Lieverse et  al., 1995). Moreover, a variety of studies conducted 
over the past several decades show that CCK-induced satiation 
is mediated by the vagus nerve (Smith et al., 1981, 1985; Schwartz 
and Moran, 1994; Raybould, 2007; Dockray, 2013; Kaelberer 
et  al., 2018; Schwartz, 2018); however, selected studies show 
that gut-derived CCK may additionally interact with CCK-A 
receptors in the brain (Reidelberger et  al., 2004; Ripken et  al., 
2015). We  used the brain-penetrant CCK-A receptor antagonist, 
devazepide, in our studies; therefore, we  cannot rule out the 
possibility that CCK-A receptors in the brain participate in the 
appetite-suppressing effects of CCK release following inhibition 
of peripheral CB1Rs. Thus, given discrepancies in the literature 
regarding the underlying mechanisms of gut-brain signaling and 
its dysregulation in DIO, it is critical to examine the impact of 
diet and obesity on gut-brain satiation signaling using reliable 
and reproducible model systems.
It is plausible that CB1R control of nutrient-induced CCK 
release is one of several mechanisms by which peripheral CB1Rs 
impact gut-brain signaling pathways (Burdyga et al., 2004, 2006; 
Cluny et al., 2013). For example, administration of ghrelin – which 
is produced in the stomach and upper small intestinal epithelium 
and increases feeding [see for review, (Steinert et  al., 2017; 
Kaelberer and Bohorquez, 2018)] – blocked downregulation 
of CB1Rs in the nodose ganglion after, both, re-feeding and 
CCK administration in fasted rats (Burdyga et  al., 2006). 
Moreover, pharmacological inhibition of CB1Rs blocked fasting-
induced ghrelin production in rats (Cani et al., 2004; Al-Massadi 
et  al., 2011; Senin et  al., 2013), which suggests that CB1Rs in 
the upper GI tract may control ghrelin signaling. Furthermore, 
Kunos and colleagues reported that a peripherally-restricted 
CB1R inverse agonist improved a host of metabolic parameters 
as well as reducing food intake in DIO mice by a mechanism 
that may include reversing hyperleptinemia and leptin resistance 
associated with DIO (Tam et  al., 2012) and restoring anorexic 
melanocortin signaling in the arcuate nucleus of the hypothalamus 
(Tam et  al., 2017). Bellocchio and colleagues reported that the 
hypophagic effects of CB1R inhibition with the CB1R inverse 
agonist, rimonabant, is blocked by pharmacological inhibition 
of peripheral beta-adrenergic neurotransmission (Bellocchio 
et al., 2013), which suggests that CB1Rs may additionally control 
feeding behavior via interactions with the peripheral sympathetic 
nervous system. This study also showed that intact afferent 
vagal signaling was required for the hypophagic effects of 
rimonabant, and CB1Rs in the brain were not required for its 
pharmacological actions. Nonetheless, circulating levels of the 
eCBs increase in human and rodent models of obesity (Engeli 
et  al., 2005; Bluher et  al., 2006; Cote et  al., 2007; Di Marzo 
et  al., 2009; Matias et  al., 2012; Argueta and DiPatrizio, 2017; 
Hillard, 2017; Simon and Cota, 2017; Little et al., 2018), which 
may directly interact with CB1Rs in the brain and control 
feeding behavior and energy homeostasis. A comprehensive 
analysis of this possibility remains to be performed. In addition 
to I-cells in the small intestinal epithelium (see Figures 1, 2; 
Sykaras et  al., 2012), CB1Rs are also expressed in K-cells that 
produce and secrete glucose-dependent insulinotropic peptide 
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[GIP (Moss et  al., 2012; Reimann and Gribble, 2016)]. 
Pharmacological activation of CB1Rs inhibits GIP release in 
rodents, which suggests that local CB1Rs may impact glucose 
homeostasis via a mechanism that includes controlling nutrient-
induced incretin release. Lastly, enteroendocrine cells in the 
intestinal lining form functional synapses with afferent vagal 
fibers (Kaelberer et al., 2018). Termed “neuropods” by Bohorquez 
and colleagues, these cells sense nutrients and release glutamate 
and CCK in a coordinated manner that interact with 
corresponding receptors on local afferent vagal fibers, which 
in turn, communicate with the brain. Our data suggest that 
CB1Rs may be at the interface of this signaling. It is unknown, 
however, if CB1Rs control glutamate signaling at these synapses 
in the small intestine as they do in the brain (Jung et  al., 
2007). Collectively, these studies—in combination with the 
present report—describe key roles for peripheral CB1Rs in 
feeding behavior and energy homeostasis.
In summary, our results provide evidence of a previously 
unknown mechanism of CB1R-mediated inhibition of gut-brain 
satiation signaling in DIO that promotes overeating. 
Pharmacological manipulation of these pathways in the periphery 
may provide a therapeutic advantage for the treatment of obesity 
and related metabolic disorders when compared to anti-obesity 
drugs that interact with the brain and display psychiatric side-
effects (Christensen et  al., 2007; Khera et  al., 2016). Despite 
the peripherally-restricted properties of these CB1R antagonists, 
however, their impact on cognition and brain function by altering 
gut microbe activity is unknown and remains to be  reported.
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